Bill Alpert's "This Small Biotech Is Partnering With Johnson & Johnson. The Stock Could More Than Double" discusses how MeiraGTx Holdings PLC (NASDAQ:MGTX) is quietly working on a promising new approach to gene therapy. See why Barron's believes that is an opportunity for investors, in an article that both sizes up the opportunity and ponders the unknowns.

U.S. Food and Drug Administration drug rulings expected in the coming months could affect the stocks of big pharmaceutical companies like Eli Lilly And Co (NYSE:LLY) and biotechs like BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). So says "FDA Is About to Make Some Major Drug Decisions" by Josh Nathan-Kazis.

In Ben Levisohn's "These 5 Stocks Control the Stock Market. Things Are About to Get Interesting," a case is made for the idea that as Amazon.com, Inc. (NASDAQ:AMZN), Apple Inc (NASDAQ:AAPL) and other tech giants go, so goes the S&P 500. Find out why Barron's recommends keeping an eye on the 10-year Treasury yield and on regulators' agendas.

"3 Stocks to Beat Inflation: Chevron, Citigroup, and Newmont" by Carleton English explores how high-dividend-paying stocks can serve as bond proxies for yield-hungry investors. And is there a chance for some stock appreciation at Chevron Corporation (NYSE:CVX) and Citigroup Inc (NYSE:C) as well?

• The next big thing in biotech


• A look back at the Black Monday market crash


• Why investors should be wary of big tech earnings


• How big a concern the threat of stagflation is


• How to play India's stock market momentum


• Why China has good reason to fear Bitcoin


• After decent third-quarter earnings, what is next for big banks


• A flexible fund for income-hungry investors


• Where the workers who did not come back went